Expression of miR-425-5p in Pancreatic Carcinoma and Its Correlation with Tumor Immune Microenvironment

References

• Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):1–7. doi:10.1038/s41575-021-00457-x.
   PubMed Web of Science ®Google Scholar
• Sun K, Mylavarapu C, Crenshaw A, et al. Pancreatic head vs pancreatic body/tail cancer: are they different? World J Gastrointest Oncol. 2022;14(3):716–723. doi:10.4251/wjgo.v14.i3.716.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Girish BP, Dariya B, Mannarapu M, Nagaraju GP, Raju GSR. Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Semin Cancer Biol. 2022;86(Pt 2):1155–1162. doi:10.1016/j.semcancer.2021.06.014.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic adenocarcinoma: unconventional approaches for an unconventional disease. Cancer Res. 2020;80(16):3179–3192. doi:10.1158/0008-5472.CAN-19-2731.
   PubMed Web of Science ®Google Scholar
• Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019;20(5):1836–1852. doi:10.1093/bib/bby054.
   PubMed Web of Science ®Google Scholar
• Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs’ action through miRNA editing. IJMS. 2019;20(24):6249. doi:10.3390/ijms20246249.
   Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465. doi:10.1002/jcp.27486.
   PubMed Web of Science ®Google Scholar
• Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory mechanism of microRNA expression in cancer. IJMS. 2020;21(5):1723. doi:10.3390/ijms21051723.
   Google Scholar
• Yan YF, Gong FM, Wang BS, Zheng W. MiR-425-5p promotes tumor progression via modulation of CYLD in gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:2130–2136.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang H, Cui M, Chen C, Feng Y. Hsa-miR-425-5p promotes tumor growth and metastasis by activating the CTNND1-mediated beta-catenin pathway and EMT in colorectal cancer. Cell Cycle. 2020;19(15):1917–1927. doi:10.1080/15384101.2020.1783058.
   PubMed Web of Science ®Google Scholar
• Zhou JS, Yang ZS, Cheng SY, Yu JH, Huang CJ, Feng Q. miRNA-425-5p enhances lung cancer growth via the PTEN/PI3K/AKT signaling axis. BMC Pulm Med. 2020;20(1):223. doi:10.1186/s12890-020-01261-0.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wu X, Wang J. Correlation of miR-425-5p and IL-23 with pancreatic cancer. Oncol Lett. 2019;17(5):4595–4599. doi:10.3892/ol.2019.10099.
   PubMed Web of Science ®Google Scholar
• Lv B, Wang Y, Ma D, et al. Immunotherapy: reshape the tumor immune microenvironment. Front Immunol. 2022;13:844142. doi:10.3389/fimmu.2022.844142.
   PubMedGoogle Scholar
• Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. doi:10.1186/s12943-018-0858-1.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between constitutive and inducible chemokines enables t cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900 e810. doi:10.1016/j.ccell.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol. 2021;27(40):6775–6793. doi:10.3748/wjg.v27.i40.6775.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782.
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080–2089. doi:10.1111/cas.14069.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6(3):235–246. doi:10.1158/2159-8290.CD-15-0893.
   PubMed Web of Science ®Google Scholar
• Lippi G, Mattiuzzi C. The global burden of pancreatic cancer. Arch Med Sci. 2020;16(4):820–824. doi:10.5114/aoms.2020.94845.
   PubMed Web of Science ®Google Scholar
• Ariston Gabriel AN, Wang F, Jiao Q, et al. The involvement of exosomes in the diagnosis and treatment of pancreatic cancer. Mol Cancer. 2020;19(1):132. doi:10.1186/s12943-020-01245-y.
   PubMed Web of Science ®Google Scholar
• Liu L, Kshirsagar PG, Gautam SK, et al. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics. 2022;12(3):1030–1060. doi:10.7150/thno.64805.
   PubMedGoogle Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1.
   PubMed Web of Science ®Google Scholar
• He B, Zhao Z, Cai Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci. 2020;16(14):2628–2647. doi:10.7150/ijbs.47203.
   PubMed Web of Science ®Google Scholar
• Pushalkar S, Ji X, Li Y, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012;12:144. doi:10.1186/1471-2180-12-144.
   PubMed Web of Science ®Google Scholar
• Feng Y, Tong X, Zhang B, Mao G, Huang H, Ma H. Effect of FAM196B in human lung adenocarcinoma. J Cancer. 2018;9(14):2451–2459. doi:10.7150/jca.24907.
   PubMed Web of Science ®Google Scholar
• Pan R, Zhou C, Dai J, et al. Endothelial PAS domain protein 1 gene hypomethylation is associated with colorectal cancer in Han Chinese. Exp Ther Med. 2018;16(6):4983–4990. doi:10.3892/etm.2018.6856.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Dou H, Liu Y, et al. Breast cancer exosome-derived miR-425-5p induces cancer-associated fibroblast-like properties in human mammary fibroblasts by TGFbeta1/ROS signaling pathway. Oxid Med Cell Longev. 2022;2022:5266627. doi:10.1155/2022/5266627.
   PubMed Web of Science ®Google Scholar
• Wu H, Shang J, Zhan W, Liu J, Ning H, Chen N. miR‑425‑5p promotes cell proliferation, migration and invasion by directly targeting FOXD3 in hepatocellular carcinoma cells. Mol Med Rep. 2019;20(2):1883–1892. doi:10.3892/mmr.2019.10427.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Y, Liu R, Meng Y, Tian G, Cao Q. Downregulation of microRNA-425-5p suppresses cervical cancer tumorigenesis by targeting AIFM1. Exp Ther Med. 2019;17(5):4032–4038. doi:10.3892/etm.2019.7408.
   PubMed Web of Science ®Google Scholar
• Makler A, Narayanan R, Asghar W. An exosomal miRNA biomarker for the detection of pancreatic ductal adenocarcinoma. Biosensors (Basel). 2022;12(10):831. doi:10.3390/bios12100831.
   PubMedGoogle Scholar
• Daoud AZ, Mulholland EJ, Cole G, McCarthy HO. MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer. 2019;19(1):1130. doi:10.1186/s12885-019-6284-y.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wen M, Guo J, et al. Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer. Pathol Res Pract. 2017;213(8):929–937. doi:10.1016/j.prp.2017.05.009.
   PubMed Web of Science ®Google Scholar
• Fu Y, Li Y, Wang X, Li F, Lu Y. Overexpression of miR-425-5p is associated with poor prognosis and tumor progression in non-small cell lung cancer. Cancer Biomark. 2020;27(2):147–156. doi:10.3233/CBM-190782.
   PubMed Web of Science ®Google Scholar
• Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188409. doi:10.1016/j.bbcan.2020.188409.
   PubMed Web of Science ®Google Scholar
• Luo Z, Rong Z, Zhang J, et al. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression. Mol Cancer. 2020;19(1):86. doi:10.1186/s12943-020-01203-8.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wang YL, Yao WJ, et al. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015;8:824–829.
   PubMed Web of Science ®Google Scholar
• Ni X, Chen C, Cui G, Ding W, Liu J. Crosstalk of RNA adenosine modification-related subtypes, establishment of a prognostic model, and immune infiltration characteristics in ovarian cancer. Front Immunol. 2022;13:932876. doi:10.3389/fimmu.2022.932876.
   PubMed Web of Science ®Google Scholar
• Chen F, Li J, Wang H, Ba Q. Anti-tumor effects of Chinese medicine compounds by regulating immune cells in microenvironment. Front Oncol. 2021;11:746917. doi:10.3389/fonc.2021.746917.
   PubMed Web of Science ®Google Scholar
• Fu T, Dai LJ, Wu SY, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98. doi:10.1186/s13045-021-01103-4.
   PubMed Web of Science ®Google Scholar
• Huber M, Brehm CU, Gress TM, et al. The immune microenvironment in pancreatic cancer. IJMS. 2020;21(19):7307. doi:10.3390/ijms21197307.
   Google Scholar
• Fu X, Sun G, Tu S, et al. Hsa_circ_0046523 mediates an immunosuppressive tumor microenvironment by regulating miR-148a-3p/PD-L1 axis in pancreatic cancer. Front Oncol. 2022;12:877376. doi:10.3389/fonc.2022.877376.
   PubMed Web of Science ®Google Scholar
• Gartrell RD, Enzler T, Kim PS, et al. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. Oncoimmunology. 2022;11(1):2066767. doi:10.1080/2162402X.2022.2066767.
   PubMed Web of Science ®Google Scholar
• Guo Q, Li J, Lin H. Effect and molecular mechanisms of traditional Chinese medicine on regulating tumor immunosuppressive microenvironment. Biomed Res Int. 2015;2015:261620. doi:10.1155/2015/261620.
   PubMed Web of Science ®Google Scholar
• Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L. IFN-gamma down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer. 2019;19(1):1053. doi:10.1186/s12885-019-6145-8.
   PubMed Web of Science ®Google Scholar
• Sempere LF, Powell K, Rana J, Brock AA, Schmittgen TD. Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer. Cancer Metastasis Rev. 2021;40(3):761–776. doi:10.1007/s10555-021-09995-x.
   PubMed Web of Science ®Google Scholar
• Wang B, Xiao H, Yang X, et al. A novel immune-related microRNA signature for prognosis of thymoma. Aging (Albany NY). 2022;14(11):4739–4754. doi:10.18632/aging.204108.
   PubMedGoogle Scholar